Corporate | 16 April 2010 07:30
4SC AG / Miscellaneous
16.04.2010 07:30
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg-Martinsried and Bonn, Germany - 16 April, 2010 - 4SC AG
(Frankfurt, Prime Standard: VSC), a drug discovery and development company
focused on autoimmune and cancer indications, and the Bonn (Germany) based
Nexigen GmbH, a company which conducts the discovery and development of
novel peptide compounds for cancer, today announced their cooperation. The
joint project aims to develop novel peptide cancer therapeutics and is
being funded with EUR 1.4 million by the German Federal Ministry of
Education and Research (Bundesministerium für Bildung und Forschung - BMBF)
under the KMU-Innovation Programme.
The objective of the collaboration is the development of novel peptide
therapies for the treatment of cancers that are linked to the Wnt signaling
pathway. The dysfunction of this signaling pathway is particularly
prevalent in colon and prostate cancer cells. This approach may establish
a new class of peptide based therapeutics for the treatment of cancers such
as colon and prostate tumours, for which the prognosis is especially low
and current therapeutic treatment options are not sufficient.
In this cooperation Nexigen will apply its proprietary intracellular
peptides screening technology to identify novel molecules. These should,
with the support of 4SC's technology and development expertise, advance
into the clinical development phase.
'We are very happy about the dual support of our proprietary peptide based
approach through the external validation of the BMBF funding and the
cooperation with 4SC. With this the unique combination of Nexigen's
peptide platform and 4SC's technology and development expertise has gained
a sustainable base,' said Dr. Hanjo Hennemann, founder and Managing
Director of Nexigen.
'With this cooperation and the support of the BMBF, 4SC has the possibility
to develop a new class of peptide therapeutics,' commented Daniel Vitt,
Chief Scientific Officer of 4SC. 'Such therapeutics could affect disease
targets that are not currently treatable with classical chemotherapy or
with antibodies.'
For further information please contact:
4SC AG
Yvonne Alexander
Investor & Public Relations
Tel: +49 (0) 89 70 07 63 66
yvonne.alexander@4sc.com
Nexigen GmbH
Daniela Mecklenbroich
Tel.: +49 (0) 228 53 68 56 - 0
mecklenbroich@nexigen.de
MC Services
Stefan Riedel
Tel.: +49 (0) 89 21 02 28 40
stefan.riedel@mc-services.eu
Notes to Editor
About 4SC
4SC AG (ISIN DE0005753818) is a drug discovery and development company
focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a
small molecule, is currently in a Phase IIb study in rheumatoid arthritis
and a Phase IIa exploratory study in inflammatory bowel disease. The
company's lead oncology compound, resminostat (4SC-201), a pan histone
deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular
carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203
and 4SC-205, are in Phase I studies. 4SC develops drug candidates until
proof-of-concept in order to generate value creating partnerships with the
pharmaceutical industry in return for advance and milestone payments as
well as royalties.
4SC was founded in 1997, has 91 employees, and is listed on the Prime
Standard of the Frankfurt Stock Exchange since December 2005.
You will find further information under www.4sc.com.
About Nexigen
Nexigen GmbH identifies and develops peptide based therapeutics primarily
for cancer. The company is focused on affecting disease mechanisms that
cannot be treated with current therapeutics, such as small-molecules and
antibodies. Nexigen's technology is based on a proprietary, patented
screening system of peptides in living cells. In order to optimise peptide
compounds the technology platform integrates bioinformatic, cellular in
vitro testsystems as well as peptide chemistry. Nexigen has already
completed a number of projects with big pharma and biotechnology companies.
Nexigen's strategy is based on the development of its own compounds and
selective partnerships in the life-science industry.
Nexigen (www.nexigen.de) has 14 employees and was established in 2007 as a
spin-off from the caesar research institute in Bonn, Germany.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
16.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Deutschland
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------